Современные представления об особенностях микробиоценоза влагалища у ВИЧ-позитивных женщин фертильного возраста

1. Экспресс-информация об эпидемической ситуации по ВИЧ-инфекции на 01.01. 2019 г. по Иркутской области. Центр СПИД.

2. Янковский Д.С., Дымент Г.С. Использование пробиотиков с целью улучшения репродуктивного здоровья женщины. Здоровье женщины. 2008; 2: 161–170.

3. Плахова К.И., Гомберг М.А., Атрошкина М.Е. Роль Atopobium vaginae при рецидивировании бактериального вагиноза. Вестник дерматологии и венерологии. 2007; 5: 9–13.

4. Рахматулина М.Р., Плахова К.И. Бактериальный вагиноз, ассоциированный с Atopobium vaginae: cовременные принципы диагностики и терапии. Акушерство и гинекология. 2012; 3: 88–92.

5. Ferris M.J., Masztal A., Aldridge K.E., Fortenberry J.D., Fidel P.L. Jr., Martin D.H. Association of Atopobium vaginae, a recently described metronidazole resistant anaerobe, with bacterial vaginosis. BMC Infectious Diseases. 2004; 4: 5–8. doi: 10.1186/1471-2334-4-5
6. Verhelst R., Verstraelen H., Claeys G., Temmerman M., Vaneechoutte M. Culture-independent analysis of vaginal microflora: the unrecognized association of Atopobium vaginae with bacterial vaginosis. Am J Obstet Gynecol. 2004; 191(4): 1130–2. doi: 10.1016/j.ajog.2004.04.013
7. McGregor J., French L. Bacterial vaginosis in pregnancy. Obstet Gynecol Surv. 2000; 55: 1–19. doi: 10.1097/00006254-200005001-00001
8. Nunn K.L., Wang Y.Y., Harit D., Humphrys M.S., Ma B., Cone R., et al. Enhanced Trapping of HIV-1 by Human Cervicovaginal Mucus Is Associated with Lactobacillus crispatus-Dominant Microbiota. MBio. 2015; 6(5): e01084–15. doi: 10.1128/mBio.01084-15
9. Hill J.E., Goh S.H., Money D.M., Doyle M., Li A., Crosby W.L., Links M., et al. Characterization of vaginal microflora of healthy, nonpregnant women by haperonin-60 sequence-based methods. Am J Obstet Gynecol. 2005;193(3 Pt 1): 682–92. doi: 10.1016/j.ajog.2005.02.094
10. Колесникова Л.И., Даренская М.А., Рашидова М.А., Шолохов Л.Ф., Гребенкина Л.А., Лещенко О.Я., Тимофеева Е.В. Оценка показателей оксидативного стресса у женщин с ВИЧ моно- и коинфекцией. Инфекционные болезни. 2016; 14(S1): 138. eLIBRARY ID: 26658883
11. Kolesnikova L., Darenskaya M., Grebenkina L., Timofeeva E., Leshenko O., Semenova N., Kurashova N., Vanteeva O. Oxidative stress parameters in women with HIV and HIV/hepatitis B and/or C co-infection. Journal of AIDS and Clinical Research. 2014; 5(11): 5–11.
12. Monaco C.L., Gootenberg D.B., Zhao G., Handley S.A., Ghebremichael M.S., Lim E.S., et al. Altered Virome and Bacterial Microbiome in Human Immunodeficiency Virus-Associated Acquired Immunodeficiency Syndrome. Cell Host Microbe. 2016; 19(3): 311–22. doi: 10.1016/j.chom.2016.02.011.

13. Медведева О.А., Королев В.А., Авдеева Ю.А. Состояние микробиоценоза толстого кишечника и прооксидантно-антиоксидантного баланса колоноцитов в условиях экспериментального дисбиоза и профилактики мексидолом. Научные ведомости Белгородского государственного университета. Серия: Медицина. Фармация. 2017; 5(254): 134–40.

14. Marianian A., Timofeeva E., Atalyan A., Leshchenko O., Suturina L., Balachova T. Alcohol use, pregnancy planning, and reproductive health concerns in people living with HIV/AIDS in Russia. Alcoholism: Clinical and Experimental Research. 2018; 42(6): 76–79.eLIBRARY ID: 36082804
15. Chehoud C., Stieh D.J., Bailey A.G., Laughlin A.L., Allen S.A., McCotter K.L., Sherrill-Mix S.A., Hope T.J., Bushman F.D., et al. Associations of the vaginal microbiota with HIV infection, bacterial vaginosis and demographic factors. AIDS. 2017; 31(7): 895–904. doi: 10.1097/QAD.0000000000001421.
16. Gosmann C., Anahtar M.N., Handley S.A., Farcasanu M., Abu-Ali G., Bowman B.A., Padavattan N., Desai C., Droit L., Moodley A., Dong M., Chen Y., Ismail N., Ndung’u T., Ghebremichael M.S., Wesemann D.R., Mitchell C., Dong K.L., Huttenhower C., Walker B.D., Virgin H.W., Kwon D.S. Lactobacillus-Deficient Cervicovaginal Bacterial Communities are Associated with Increased HIV Acquisition in Young South African Women. Immunity. 2017; 46(1): 29–37. doi: 10.1016/j.immuni.2016.12.013
17. Atashili J., Poole C., Ndumbe P.M., Adimora A.A., Smith J.S. Bacterial vaginosis and HIV acquisition: a meta-analysis of published studies. AIDS. 2008; 22(12): 1493–1501. doi: 10.1097/QAD.0b013e3283021a37.
18. Passmore J.-A.S., Jaspan H.B., Masson L. Genital inflammation, immune activation and risk of sexual HIV acquisition. Curr Opin HIV AIDS. 2016;11(2): 156–62. doi: 10.1097/COH.0000000000000232.
19. Masese L., Baeten J.M., Richardson B.A., Bukusi E., John-Stewart G., Graham S.M. et al. Changes in the contribution of genital tract infections to HIV acquisition among Kenyan high-risk women from 1993 to 2012. AIDS. 2015; 29(9):1077–85. doi: 10.1097/QAD.0000000000000646.
20. Coleman J.S., Hitti J., Bukusi E.A., Mwachari C., Muliro A., Nguti R. et al. Infectious correlates of HIV-1 shedding in the female upper and lower genital tracts. AIDS. 2007; 21: 755–59. doi: 10.1097/QAD.0b013e328012b838
21. Martin D. The microbiota of the vagina and its influence on women’s health and disease. Am J Med Sci. 2012; 343(1): 2–9. doi: 10.1097/MAJ.0b013e31823ea228.
22. Mirmonsef P., Krass L., Landay A. The role of bacterial vaginosis and trichomonas in HIV transmission across the female genital tract. Curr. HIV Res. 2012; 10: 202–10. doi: 10.2174/157016212800618165
23. Mbizvo E.M., Msuya S.E., Stray-Pedersen B. HIV seroprevalence and its associations with the other reproductive tract infections in asymptomatic women in Harare, Zimbabwe. Int J STD AIDS. 2001; 12: 524–31. doi: 10.1258/0956462011923624
24. Eade C.R., Diaz C., Chen S., Cole A.L., Cole A.M. HIV-Enhancing Factors Are Secreted by Reproductive Epithelia upon Inoculation with Bacterial Vaginosis-Associated Bacteria. Protein Pept Lett. 2015; 22: 672–80. doi: 10.2174/0929866522666150309155735
25. Jespers V., Crucitti T., van de Wijgert J., Vaneechoutte M., Delany-Moretlwe S., Mwaura M. A DNA tool for early detection of vaginal dysbiosis in African women. Res Microbiol. 2015; 11: 180–1. doi: 10.1016/j.resmic.2015.10.006.
26. Adimora A.A., Ramirez C., Auerbach J.D., Aral S.O., Hodder S., Wingood G. et al. Preventing HIV infection in women. J Acquir Immune Defic Syndr. 2013; 63(02): 168–73. doi: 10.1097/QAI.0b013e318298a166
27. Caceres C.F., O’Reilly K.R., Mayer K.H., Baggaley R. PrEP implementation: moving from trials to policy and practice. J Int AIDS Soc. 2015; 18(4): 202–22. doi: 10.7448/IAS.18.4.20222.
28. Baeten J.M., Donnell D., Ndase P., Mugo N.R., Campbell J.D., Wangisi J, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012; 367(5): 399–410. doi: 10.1056/NEJMoa1108524.
29. Thigpen M.C., Kebaabetswe P.M., Paxton L.A., Smith D.K., Rose C.E., Segolodi T.M. et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012; 367(5): 423–34. doi: 10.1056/NEJMoa1110711.
30. Baeten J.M., Palanee-Phillips T., Brown E.R., Schwartz K., Soto-Torres L.E., Govender V. et al. Use of a vaginal ring containing dapivirine for HIV-1 prevention in women. N Engl J Med. 2016; 375: 2121–2132. doi: 10.1056/NEJMoa1506110.
31. Nel A., van Niekerk N., Kapiga S., Bekker L.-G., Gama C., Gill K. et al. Safety and efficacy of a dapivirine vaginal ring for HIV prevention in women. N Engl J Med. 2016; 375(22): 2133–43. doi: 10.1056/NEJMoa1602046.
32. Schlesinger E., Johengen D., Luecke E., Rothrock G., McGowan I., van der Straten A., et al. A tunable, biodegradable, thin-film polymer device as a long-acting implant delivering tenofovir alafenamide fumarate for HIV pre-exposure prophylaxis. Pharm Res. 2016; 33(7): 1649–56. doi: 10.1007/s11095-016-1904-6.
33. Klatt N.R., Cheu R., Birse K., Zevin A.S., Perner M., Noel-Romas L. et al. Vaginal bacteria modify HIV tenofovir microbicide efficacy in African women. Science. 2017; 356: 938–45. doi: 10.1126/science.aai9383.
34. Anahtar M.N., Byrne E.H., Doherty K.E., Bowman B.A., Yamamoto H.S., Soumillon M. et al. Cervicovaginal bacteria are a major modulator of host inflammatory responses in the female genital tract. Immunity. 2015; 42(5): 965–976. doi: 10.1016/j.immuni.2015.04.019.
35. Akil A., Agashe H., Dezzutti C.S., Moncla B.J., Hillier S.L., Devlin B., et al. Formulation and characterization of polymeric films containing combinations of antiretrovirals (ARVs) for HIV prevention. Pharm Res. 2015; 32(2): 458–68. doi: 10.1007/s11095-014-1474-4.
36. Heffron R.A. Oral PrEP is efficacious for HIV prevention among women with abnormal vaginal microbiota. Lancet HIV. 2017; 4(10): 449–56. doi: 10.1016/S2352-3018(17)30110-8.
37. Hendrix C.W., Chen B.A., Guddera V., Hoesley C., Justman J., Nakabiito C. et al. MTN-001: randomized pharmacokinetic cross-over study comparing tenofovir vaginal gel and oral tablets in vaginal tissue and other compartments. PloS One. 2013; 8(1): 550–613. doi: 10.1371/journal.pone.0055013.
38. Hillier S.L., Meyn L., Bunge K., Austin M., Moncla B.J., Dezzutti C. et al. Impact of vaginal microbiota on genital tissue and plasma concentrations of tenofovir. CROL. 2017; http://www.croiwebcasts.org/p/2017croi/croi33459
39. Oliveira P., Mascarenhas R., Lacroix C., Ferrer S.R., C Oliverira R.P., Cravo E.A., et al. Braz J Infect Dis Candida species isolated from the vaginal mucosa of HIV-infected women in Salvador, Bahia, Brazil.2011;15: 239–44. doi: 10.1016/s1413-8670(11)70182-9
40. Lallar M., Nanda S., Nandal R. Lower Genital Tract Infections in HIV-Infected Women: Can We Afford to Miss? J Obstet Gynecol India. 2015; 65: 45. https://doi.org/10.1007/s13224-014-0604-6
41. Cohen C. J., Kuritzkes D.R.HIV essentials. Jones and Bartlett Learning, 2008; 192 p.
42. Hall J., Hall B., Cockerell C. HIV/AIDS in the post-HAART era: Manifestations, treatment, and epidemiology. PMPH-USA, 2011; 1019 p. https://books.google.ru/books?id=9TR6XuLNhIUC
43. Volberding P., Greene W., Lange J.M.A., Gallant J.E., Sewankambo N. Sande’s HIV/AIDS medicine: Medical management of AIDS 2013; Elsevier Health Sciences, 2012; 596 p. https://books.google.ru/books?id=DrsIKtpVimUC
44. Saag M.S., Pavia, A.T., Chambers, H.F., Eliopoulos G.M., Gilbert D.N., ed. The Sanford guide to HIV/AIDS therapy. Antimicrobial Therapy Inc., 2017; 186 p. ISBN-13: 978-1944272050

Поступила 17.04.2019

Принята в печать 19.04.2019